Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Terminated
23 enrolled
Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma
Phase 1 Terminated
7 enrolled
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Phase 1 Terminated
18 enrolled
PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia
Phase 2 Terminated
40 enrolled
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
Phase 1 Terminated
84 enrolled
Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma
Phase 1/2 Terminated
20 enrolled 34 charts
Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 Terminated
1 enrolled
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Phase 1 Terminated
1 enrolled
ZUMA-25
Phase 2 Terminated
19 enrolled 28 charts
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
Phase 1/2 Terminated
42 enrolled
EXPAND
Phase 2 Terminated
2 enrolled 8 charts
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
Phase 1/2 Terminated
8 enrolled 11 charts
An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
Phase 1 Terminated
69 enrolled 47 charts
SPARK-ALL: Calaspargase Pegol in Adults With ALL
Phase 2/3 Terminated
42 enrolled
topMIND
Phase 1/2 Terminated
54 enrolled 23 charts
A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
Phase 1 Terminated
22 enrolled
TOUCH
Phase 1/2 Terminated
56 enrolled
TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Phase 1/2 Terminated
19 enrolled
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
Phase 2 Terminated
14 enrolled 15 charts
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Phase 1/2 Terminated
130 enrolled
ELiPSE-1
Phase 1 Terminated
28 enrolled
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase 1/2 Terminated
101 enrolled
A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas
Phase 1 Terminated
1 enrolled
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Phase 1/2 Terminated
93 enrolled 27 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Phase 1 Terminated
84 enrolled
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
Phase 1 Terminated
15 enrolled
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL
Phase 1 Terminated
25 enrolled
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
Phase 1 Terminated
37 enrolled
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Phase 1/2 Terminated
9 enrolled 20 charts
A Study of Isatuximab-based Therapy in Participants With Lymphoma
Phase 1/2 Terminated
58 enrolled 37 charts
ISAKIDS
Phase 2 Terminated
67 enrolled 25 charts
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase 1/2 Terminated
6 enrolled 17 charts
LYMFOR
Phase 3 Terminated
13 enrolled
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Phase 2 Terminated
255 enrolled 29 charts
LuminICE-203
Phase 2 Terminated
25 enrolled 21 charts
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
Phase 1 Terminated
139 enrolled
MK-2118-001
Phase 1 Terminated
140 enrolled 37 charts
ALEXANDER
Phase 1/2 Terminated
52 enrolled 29 charts
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Phase 1 Terminated
55 enrolled
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
Phase 2 Terminated
81 enrolled
Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas
Phase 1 Terminated
53 enrolled 27 charts
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Phase 1 Terminated
13 enrolled 10 charts
GLEAN-1
Phase 1 Terminated
34 enrolled
Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
Phase 1 Terminated
203 enrolled 43 charts
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
Phase 1/2 Terminated
196 enrolled 28 charts
PROBE
Phase 1 Terminated
31 enrolled
SWATCH
Phase 1/2 Terminated
54 enrolled
Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Phase 1/2 Terminated
178 enrolled 33 charts
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
Phase 4 Terminated
10 enrolled 12 charts